C12N 2770/32171
Demonstrated in vivo effect
C12N2770/32171 (Demonstrated in vivo effect) appears on 11 US grants and 17 published applications in this corpus.
Search patents in C12N- Granted patents
- 11
- Published applications
- 17
- Assignees
- 13
- Inventors
- 57
- Latest grant
- 9 Apr 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 1 | 1 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 2 | 3 |
| 2019 | 1 | 2 |
| 2020 | 1 | 1 |
| 2021 | 3 | 1 |
| 2022 | 0 | 2 |
| 2023 | 0 | 0 |
| 2024 | 1 | 2 |
| 2025 | 0 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Recombinant foot-and-mouth disease virus with reduced immunosuppression activity, and preparation method and use thereof9 Apr 2024US 11,952,401 B2Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
- Method of purifying virus-like-particles7 Dec 2021US 11,191,824 B1The Government of the United States of America, as represented by the Secretary of Homeland Security
- Method for preparing foot-and-mouth disease vaccines25 May 2021US 11,013,794 B2
- Recombinant bivalent inactivated vaccine against foot-and-mouth disease virus, preparation method and use thereof19 Jan 2021US 10,894,081 B2Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
- Hand, foot, and mouth vaccines and methods of manufacture and use thereof20 Oct 2020US 10,806,782 B2Takeda Vaccines, Inc.
- Recombinant foot-and-mouth disease type a virus inducing strong adaptive immune response and overcoming interference from maternally-derived antibodies, and foot-and-mouth disease vaccine composition comprising same18 Jun 2026US 2026/0166137 A1Republic of Korea (Animal and Plant Quarantine Agency)
- Recombinant foot-and-mouth disease virus type o for inducing robust adaptive immune response and overcoming maternally-derived antibody interference, and foot-and-mouth disease vaccine composition comprising same20 Nov 2025US 2025/0352635 A1Republic of Korea (Animal and Plant Quarantine Agency)
- Development of mosaic vaccines against foot and mouth disease virus serotype asia1 May 2025US 2025/0134984 A1
- Method of producing a foot and mouth disease virus virus-like particle21 Nov 2024US 2024/0382579 A1Intervet Inc.
- Fmdv virus-like particle with stabilizing mutation31 Oct 2024US 2024/0358816 A1Intervet Inc.
Most cited
By later US patents
- Adenoviral vector-based foot-and-mouth disease vaccine5US 8,323,663 B2GenVec, Inc. · 2012
- FMDV and E2 fusion proteins and uses thereof1US 10,363,300 B2Boehringer Ingelheim Animal Health USA Inc. · 2019
- Recombinant bivalent inactivated vaccine against foot-and-mouth disease virus, preparation method and use thereof1US 10,894,081 B2Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences · 2021
- Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host1US 8,765,141 B2The United States of America as represented by the Secretary of Agriculture · 2014
- Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host1US 9,180,179 B1The United States of America as represented by the Secretary of Agriculture · 2015